CClinicalTrials.gg
CompletedNCT06032130Updated May 4, 2026

" Visual Characterization of Parkinson's Patients and Oculomotor or Perceptual Therapy"

An observational study in Parkinson Disease, sponsored by University of Valencia. Completed at 1 site in Spain. Open to participants aged 30 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by University of Valencia · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
160
Ages
30 Years to 100 Years
Sex
All
01

Study summary

Parkinson's disease (PD) is the second most common neurodegenerative condition worldwide, characterised by motor symptoms, but with other symptoms such as visual impairment.

The aim is to compare visual function between PD patients and healthy subjects in order to adequately characterise the visual capabilities of the PD population and perform oculomotor or perceptual therapy to find optometric solutions to slow down the visual impairment they suffer from or minimise their visual symptoms.

In the first phase, non-invasive tests will be carried out, such as measuring visual acuity, refraction, pupil diameter in different lighting conditions, sensory dominance, contrast sensitivity, colour vision, stereopsis, reading speed, binocular vision, eye movements and influence on quality of life.

In the second, visual oculomotor or perceptual exercises will be performed in a group of PD patients to assess whether there is stabilisation of impairment or improvement of these visual skills. These will be performed in a non-invasive way using simple and easy-to-use instruments or an application on an electronic device could be used.

Finally, in the third phase, those visual skills that have been treated will be re-evaluated to assess possible changes, compared with a group of PD patients who have not undergone the visual exercises.

Read the detailed description

Parkinson's disease (PD) is the second most common neurodegenerative condition worldwide. It is a movement disorder characterised by tremor, rigidity, bradykinesia and postural instability. However, 78% of PD patients report visual problems such as dry eye, reduced visual acuity, visual field defects, impaired contrast sensitivity (CS), impaired eye movements, diplopia, convergence insufficiency, impaired colour vision, visual hallucinations and problems in visual-spatial orientation. In fact, visual dysfunction is one of the initial symptoms of PD. A recent study has found that dopaminergic neurons affected in PD show physiological dysfunctions, but do not die. Currently, there is no cure for PD; treatments consist of controlling symptoms, and the earlier the disease is detected and administered, the more effective they are.

It is hypothesised that a programme of visual oculomotor therapy and/or visual perceptual learning (VPL) could slow or halt the deterioration of oculomotor ability and/or CS in these patients. Visual perceptual learning or VPL is a long-term improvement in performance on a visual task, any relatively permanent change in perception that arises from visual experience. Contrast Sensitivity or CS is the ability of the visual system to differentiate an object from the background in which it is located by the difference in contrast. It is the ability to detect differences in luminance between adjacent areas in an image.

If the results confirm the hypothesis, this study will have a great impact on the PD population because it could slow down the deterioration of oculomotor ability that 75% of them suffer from. It could also slow down the decline in CS that they suffer, as demonstrated by several studies. Consequently, patients would also experience an improvement in their quality of life, as they would be able to continue to perform activities of daily living that are affected by visual impairment such as walking, reading, driving and cooking. This would have a major impact on society as PD affects many people worldwide. In Europe, the prevalence and incidence rates of PD are estimated to be approximately 108-257/100 000 and 11-19/100 000 per year, respectively. Furthermore, this project would expand scientific knowledge because to date there is no literature that has evaluated VPL in patients with PD. However, there is research on amblyopia, Stargardt's disease and other neural pathologies, such as Huntington's disease. Likewise, with regard to oculomotor therapy, there is still a lot of research to be done, as there are few studies on this subject.

This is an analytical, longitudinal, prospective and observational study. In the first phase, to characterise the vision of the population with Parkinson's disease, non-invasive tests would be performed, such as measuring visual acuity, refraction, contrast sensitivity, colour vision, depth vision, the state of binocular vision and visual pathways and eye movements. Simultaneously, a control population will be measured to compare the data obtained in PD patients.

In a second phase, visual oculomotor and/or perceptual exercises would be performed in a group of PD patients to assess whether there is stabilisation of the impairment and/or improvement of these visual skills.

Finally, in the third phase, those visual skills that have been treated would be re-evaluated to assess possible changes, compared with a group of PD patients who have not undergone the visual exercises.

The research will be carried out at the Laboratory of Vision and Colour Sciences of the Department of Optics, Optometry and Vision Sciences of the University of Valencia, at the Arnau de Vilanova Hospital and at the Parkinson's Association of Valencia. These are the institutions from which the participants who take part in the study will come. They will do so voluntarily, will not be coerced to participate in any way and will be free to choose whether they want to participate or not, after having been explained to them what this project consists of. Furthermore, they will be able to revoke their signed consent at any time, so that they will automatically be excluded from the study and their data will not be used in the study if the patient so wishes. Furthermore, this project does not harm the patient's health and does not bring any financial benefit to the patient.

Only the members of the project will have access to the original study data. These data will be collected on paper, and the original source will be kept under lock and key in the laboratory of Vision and Colour Sciences of the Department of Optics, Optometry and Vision Sciences of the University of Valencia. For data analysis, the principal investigator will extract the data into a computer document in which each patient will be identified by a two-letter code (GP: control group; PD: Parkinson's patient) and three numbers. Not even the initials of the name will appear. Under this code, the data of each patient will be entered. This is the data that the rest of the group will see and have access to. Adverse event reporting and change management will be carried out through the Reservio platform, which will be used for appointment planning and online booking.

Data analysis will be carried out using the SPSS (Statistical Package for Social Sciences) statistical software and the Matlab numerical calculation system. The statistical analysis plan is as follows: the mean, standard deviation and normality of the samples will be performed with the Shapiro-Wilk test. Statistical comparison between groups will be performed with Student's t-test if the data follow a normal distribution or with the U-Mann-Whitney test otherwise. The statistical test used for qualitative variables will be Pearson's chi-square test.

02

Conditions studied

  • Parkinson Disease

Keywords

  • Parkinson's Disease
  • Vision
  • Ocular Motility Disorders
  • Perceptual Disorders
03

In context

Parkinson Disease

4,487 studies on the registry are indexed under Parkinson Disease; 1,082 are open to participants now.

This study's enrollment of 160 is above the median of 96 across 1,057 observational studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

University of Valencia is the lead sponsor of 349 studies on the registry; 73 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with Parkinson's Disease.

Inclusion criteria

  • Subjects without neurodegenerative diseases or systemic illnesses or ocular pathologies.
  • Subjects not taking medication with visual side effects.
  • Subjects able to perform the tests.
  • Subjects of similar age and sex as their corresponding Parkinson's patient so that both samples are age and gender matched.
  • Subjects diagnosed with Parkinson's disease.
  • Parkinson's patients classified according to the Hoehn \& Yahr Scale.

Exclusion criteria

Exclusion Criteria:

  • Subjects with ocular pathologies (such as Glaucoma, Age-Related Macular Degeneration, Retinopathies, Corneal Opacifications, Senile Cataracts, Severe Palpebral Ptosis) or systemic illnesses that may affect the visual system and alter the results (such as Severe Cardiopathies, Diabetes Mellitus, oncological diseases, systemic tissue disorders, chronic infectious diseases or conditions after organ or tissue transplantation).
  • Subjects with neurodegenerative or neural diseases other than the study itself, such as Alzheimer's disease, Devic's disease, Huntington's disease, Creutzfeldt-Jakob disease, epilepsy, ataxia, multiple sclerosis or amyotrophic lateral sclerosis.
  • Subjects taking medication that may alter any visual ability such as anxiolytics, antidepressants, sleeping pills.
  • Subjects with problems in understanding and following the tests.
  • Patients who have been previously treated under a vision therapy program.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
160 participants (actual)
Patient registry
No

Groups and cohorts

  • Parkinson Disease Group (PD)

    1. Anamnesis 2. Measurement of best visual acuity with an EDTRS (Early Treatment Diabetic Retinopathy Study) test 3. Measurement of refraction with trial frame refraction 4. Measurement of pupillary diameter under photopic and mesopic illumination conditions using a specific millimetric ruler 5. Measurement of ocular sensory dominance with the red filter test 6. Measurement of binocular vision status with the Cover Test, prism bar and Maddox wing 7. Photopic and mesopic achromatic contrast sensitivity using the Functional Test Analyzer device 8. Stereopsis using the Titmus Test 9. Colour vision using the Farnsworth-Munsell 100 Hue sorting test 10. Measurement of eye movements with aDEMd (adult Developmental Eye Movement) test and NSUCO (Northeastern State University College of Optometry) 11. Measurement of reading speed with Radner-Vissum test 12. National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25)

    Other: Clinical measurements

  • Control Group (GP)

    1. Anamnesis: name, sex, date of birth, contact, family contact, medical report, Hoehn \& Yahr classification, medication, systemic, ocular and family history, consumption of tobacco, alcohol, drugs, coffee, physical activity, eye colour, other observations 2. Measurement of best visual acuity with an EDTRS test 3. Measurement of refraction with trial frame refraction 4. Measurement of pupillary diameter under photopic and mesopic illumination conditions using a specific millimetric ruler 5. Measurement of ocular sensory dominance with the red filter test 6. Measurement of binocular vision status with the Cover Test, prism bar and Maddox wing 7. Photopic and mesopic achromatic contrast sensitivity using the Functional Test Analyzer device 8. Stereopsis using the Titmus Test 9. Colour vision using the Farnsworth-Munsell 100 Hue sorting test 10. Measurement of eye movements with aDEMd test and NSUCO 11. Measurement of reading speed with Radner-Vissum test 12. NEI VFQ-25

    Other: Clinical measurements

  • Therapy Parkinson Disease Group (TPD)

    Oculomotor exercises such as tracking eye movements, saccadic eye movements and fixations will be performed. These exercises will be performed in a non-invasive manner using simple and easy-to-use instruments. An application on an electronic device, namely the virtual reality software Visionary, could also be used. If financial resources allow, the intention is to use tablets or computers for this purpose. Perceptual learning exercises will also be carried out on an electronic device. The following variables will be collected from these exercises: time taken to carry out the tests, errors made, speed of completion, latency, etc. These will be compared before and after the exercises in the third phase. In addition, the patients will be given indications for working on these exercises at home.

    Other: Oculomotor or perceptual therapy

  • Control Parkinson Disease Group (CPD)

    These patients will not receive oculomotor or perceptual therapy. They will be evaluated in the same manner as patients who will receive therapy, both at the beginning and at the end of therapy in the other group.

    Other: Clinical measurements

Interventions

  • OtherClinical measurements

    Optometric measurements

  • OtherOculomotor or perceptual therapy

    Oculomotor or perceptual visual learning exercices

06

What researchers measure

Primary outcomes

  1. Anamnesis

    Ocular and perceptual characterization of Parkinson's Disease visual capabilities with the following measurements (1-12). Anamnesis: Asking age, allergies, ocular and systemic pathologies, family background, current treatment (if proceed), consumption of tobacco, alcohol, drugs, coffee, tea, performance of physical activity, state on the Hoehn \& Yahr classification, date of Parkinson's diagnosis and other observations.

    Time frame: 1 year

  2. Visual Acuity

    Using an EDTRS (Early Treatment Diabetic Retinopathy Study) test for distance and near vision with the patient's optical correction, scale: LogMAR.

    Time frame: 1 year

  3. Refraction

    Doing ocular compensation with trial frame refraction, units: diopters (D).

    Time frame: 1 year

  4. Pupillary diameter

    Under photopic and mesopic illumination conditions using a specific millimetric ruler, units: millimeters (mm).

    Time frame: 1 year

  5. Ocular sensory dominance

    Using the red filter test.

    Time frame: 1 year

  6. Binocular vision status

    Using the Cover Test Cover Test, Modified Thorington Test Card to phoria measurement and fusional vergence measurement with prism bar, units: prismatic diopters (Δ).

    Time frame: 1 year

  7. Achromatic CSF (Contrast Sensitivity Funtion)

    Under photopic and mesopic illumination conditions using the FACT (Funtional Acuity Contrast Test) test of the FVA (Functional Visual Analyzer) device of Stereo Optical Co., Inc.

    Time frame: 1 year

  8. Stereopsis

    Using the Wirth points of the Titmus test, units: seconds of arc (").

    Time frame: 1 year

  9. Colour vision

    Using the Farnsworth-Munsell 100 Hue sorting test and the Chromatic Threshold Measurement test.

    Time frame: 1 year

  10. Eye movements quality

    Using aDEMd (adult Developmental Eye Movement with distractors) test and NSUCO (Northeastern State University College of Optometry) test. Units: seconds (s).

    Time frame: 1 year

  11. Reading speed

    Using Radner-Vissum test, units: seconds (s).

    Time frame: 1 year

  12. Life quality assessment

    Scoring the National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25). Higher scores mean a better outcome. Minimum value: 0, maximum value: 100.

    Time frame: 1 year

Secondary outcomes

  1. Pursuit eye movements

    Would be performed noninvasively using simple, easy-to-use instruments such as flashlights, pointers, slates, Marsden's ball, rotating devices and Groffman's visual tracing test. If financial resources permit, an application on an electronic device could also be used. From these exercises, the following variables will be collected: time spent in the performance of the exercises in seconds (s) and errors made. These will be compared before and after the therapy. In addition, the patients would be given indications for the work of these exercises at home.

    Time frame: 1 year

  2. Saccadic eye movements

    Would be performed noninvasively using simple, easy-to-use instruments such as flashlights, pointers, slates, Hart's charts, ARB charts and Ann Arbor tracing sheets. If financial resources permit, an application on an electronic device could also be used. From these exercises, the following variables will be collected: time spent in the performance of the exercises in seconds (s) and errors made. These will be compared before and after the therapy. In addition, the patients would be given indications for the work of these exercises at home.

    Time frame: 1 year

  3. Perceptual learning technique

    Perceptual learning exercises could also be performed on an electronic device with a program that displays Gabor patches. This technique consists of a task with low-contrast, progressively decreasing, sustained attention, demanding and repetitive stimuli.

    Time frame: 1 year

07

Study locations

1 site
  • Hospital Arnau de Vilanova
    Valencia, Valencia 46015, Spain
08

References and documents

Publications

  • Armstrong MJ, Okun MS. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA. 2020 Feb 11;323(6):548-560. doi: 10.1001/jama.2019.22360. PubMed 32044947 ↗
  • Armstrong RA. Visual symptoms in Parkinson's disease. Parkinsons Dis. 2011;2011:908306. doi: 10.4061/2011/908306. Epub 2011 May 25. PubMed 21687773 ↗
  • Balestrino R, Schapira AHV. Parkinson disease. Eur J Neurol. 2020 Jan;27(1):27-42. doi: 10.1111/ene.14108. Epub 2019 Nov 27. PubMed 31631455 ↗
  • Beste C, Wascher E, Dinse HR, Saft C. Faster perceptual learning through excitotoxic neurodegeneration. Curr Biol. 2012 Oct 23;22(20):1914-7. doi: 10.1016/j.cub.2012.08.012. Epub 2012 Sep 13. PubMed 22981772 ↗
  • Borm CDJM, Visser F, Werkmann M, de Graaf D, Putz D, Seppi K, Poewe W, Vlaar AMM, Hoyng C, Bloem BR, Theelen T, de Vries NM. Seeing ophthalmologic problems in Parkinson disease: Results of a visual impairment questionnaire. Neurology. 2020 Apr 7;94(14):e1539-e1547. doi: 10.1212/WNL.0000000000009214. Epub 2020 Mar 11. PubMed 32161030 ↗
  • Campbell FW, Robson JG. Application of Fourier analysis to the visibility of gratings. J Physiol. 1968 Aug;197(3):551-66. doi: 10.1113/jphysiol.1968.sp008574. PubMed 5666169 ↗
  • Ekker MS, Janssen S, Seppi K, Poewe W, de Vries NM, Theelen T, Nonnekes J, Bloem BR. Ocular and visual disorders in Parkinson's disease: Common but frequently overlooked. Parkinsonism Relat Disord. 2017 Jul;40:1-10. doi: 10.1016/j.parkreldis.2017.02.014. Epub 2017 Feb 21. PubMed 28284903 ↗
  • Fahle M. Perceptual learning: a case for early selection. J Vis. 2004 Oct 26;4(10):879-90. doi: 10.1167/4.10.4. PubMed 15595892 ↗
  • Gonzalez-Rodriguez P, Zampese E, Stout KA, Guzman JN, Ilijic E, Yang B, Tkatch T, Stavarache MA, Wokosin DL, Gao L, Kaplitt MG, Lopez-Barneo J, Schumacker PT, Surmeier DJ. Disruption of mitochondrial complex I induces progressive parkinsonism. Nature. 2021 Nov;599(7886):650-656. doi: 10.1038/s41586-021-04059-0. Epub 2021 Nov 3. PubMed 34732887 ↗
  • Han G, Han J, Han K, Youn J, Chung TY, Lim DH. Visual Acuity and Development of Parkinson's Disease: A Nationwide Cohort Study. Mov Disord. 2020 Sep;35(9):1532-1541. doi: 10.1002/mds.28184. Epub 2020 Jul 25. PubMed 32710579 ↗
  • Huang CB, Zhou Y, Lu ZL. Broad bandwidth of perceptual learning in the visual system of adults with anisometropic amblyopia. Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):4068-73. doi: 10.1073/pnas.0800824105. Epub 2008 Mar 3. PubMed 18316716 ↗
  • Kaur M, Saxena R, Singh D, Behari M, Sharma P, Menon V. Correlation Between Structural and Functional Retinal Changes in Parkinson Disease. J Neuroophthalmol. 2015 Sep;35(3):254-8. doi: 10.1097/WNO.0000000000000240. PubMed 25807477 ↗
  • Sasaki Y, Nanez JE, Watanabe T. Advances in visual perceptual learning and plasticity. Nat Rev Neurosci. 2010 Jan;11(1):53-60. doi: 10.1038/nrn2737. Epub 2009 Dec 2. PubMed 19953104 ↗
  • Sasso P, Silvestri V, Sulfaro M, Scupola A, Fasciani R, Amore F. Perceptual learning in patients with Stargardt disease. Can J Ophthalmol. 2019 Dec;54(6):708-716. doi: 10.1016/j.jcjo.2019.03.012. Epub 2019 May 31. PubMed 31836104 ↗
  • Savitt J, Aouchiche R. Management of Visual Dysfunction in Patients with Parkinson's Disease. J Parkinsons Dis. 2020;10(s1):S49-S56. doi: 10.3233/JPD-202103. PubMed 32741840 ↗
  • Shibasaki H, Tsuji S, Kuroiwa Y. Oculomotor abnormalities in Parkinson's disease. Arch Neurol. 1979 Jun;36(6):360-4. doi: 10.1001/archneur.1979.00500420070009. PubMed 454234 ↗
  • Herrero-Gracia A, Hernandez-Andres R, Luque MJ, Diez-Ajenjo MA. Age-related changes in contrast sensitivity function under different illumination conditions. Clin Exp Optom. 2025 Sep;108(7):880-885. doi: 10.1080/08164622.2025.2483265. Epub 2025 Apr 2. PubMed 40174875 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06032130
Lead sponsor
University of Valencia
Collaborators
Asociación Parkinson Valencia, Hospital Arnau de Vilanova
Responsible party
Amparo Diez (Principal Investigator, University of Valencia) — Principal investigator
First posted
Sep 11, 2023
Start date
Nov 2, 2023
Primary completion
Apr 10, 2024
Completion
Apr 8, 2026
Last update
May 4, 2026

Study contacts

María Amparo Díez-Ajenjo, PhD
principal investigator · University of Valencia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion